Study of BGB-B2033 drug for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancer types: liver cancer (HCC), stomach cancer with high AFP levels, germ cell tumors, or a certain type of lung cancer (squamous NSCLC) that has a protein called GPC3.
- Your cancer is advanced or has spread and cannot be removed by surgery.
- You have at least one tumor that can be measured on scans.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- You have not had treatment that targets GPC3 or the 4-1BB protein before.
- You do not have active brain metastases, autoimmune disease, or need high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BG-C477 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This trial tests a new drug called GB268, which targets three different proteins (PD-1, CTLA-4, and VEGF) that help tumors grow and hide from the immune system. It is for people with advanced solid tumors who have tried standard treatments, or for whom no standard treatment is available.
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Hear when a new Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.